By a News Reporter-Staff News Editor at Health& Medicine Week Actavis, Inc. confirmed that the United States District Court for the Southern District of Florida has found United States Patent No. 6,773,720 valid and infringed by Actavis' generic version of Shire's Lialda. Actavis is reviewing the court's decision and will evaluate all available o
PARSIPPANY, N.J. Actavis Inc. said Friday a federal appeals court granted an injection that blocks it from selling a generic version of AstraZeneca PLC's asthma treatment Pulmicort Respules. The injunction was granted by the U.S. Court of Appeals for the Federal Circuit, and it bars Actavis from selling its generic until the litigation with Astra
Actavis, Inc., a leading specialty pharmaceutical company, announced today that Paul Bisaro, Actavis' President and Chief Executive Officer, will provide an overview and update of the Company's business at the Sanford C. Bernstein Twenty-Ninth Annual Strategic Decisions Conference on Thursday, May 30, 2013 at 4:00 PM Eastern Time at the Waldorf Ast
Dublin- Research and Markets has announced the addition of the " Generic Pharmaceuticals" report to their offering. Despite the Global Generic Pharmaceutical industry becoming increasingly competitive there are 42 vibrant companies across the World exploiting innovative, more profitable routes to market. Just published the Plimsoll Global Analysis-
Impax Laboratories, Inc. today announced that the Company will present at the Deutsche Bank 38 th Annual Health Care Conference on Thursday, May 30, at 12:00 p.m. Eastern Standard Time. Impax markets its generic products through its Global Pharmaceuticals division and markets its branded products through the Impax Pharmaceuticals division.
By a News Reporter-Staff News Editor at Insurance Weekly News Prime Therapeutics, a leading pharmacy benefit manager, announced that it has been awarded two Honorable Mentions in the 2012 Award for Excellence from the Journal of Managed Care Pharmacy. Generic drug discount programs were popularized in 2006 when pharmacies such as Walmart began of
Bausch& Lomb Inc. is nearing a deal to be sold to Valeant Pharmaceuticals International Inc. for about $9 billion, The Wall Street Journal reported Friday. Citing people familiar with the situation, the newspaper said Bausch& Lomb based in Rochester, N.Y., and owned by private-equity firm Warburg Pincus LLC could reach a deal with generic drug
Research and Markets has announced the addition of the "Tysabri- Forecast and Market Analysis to 2022" report to its offerings. In a release, Research and Markets noted that report highlights include:. In addition, the entry of new companies such as Sanofi/ Genzyme and F. Hoffmann-La-Roche/ Genentech will challenge the position of the established p
Research and Markets has announced the addition of the "Tysabri- Forecast and Market Analysis to 2022" report to its offerings. In a release, Research and Markets noted that report highlights include:. In addition, the entry of new companies such as Sanofi/ Genzyme and F. Hoffmann-La-Roche/ Genentech will challenge the position of the established p
Research and Markets has announced the addition of the " Generic Pharmaceuticals" report to their offering. Despite the Global Generic Pharmaceutical industry becoming increasingly competitive there are 42 vibrant companies across the World exploiting innovative, more profitable routes to market. Just published the Plimsoll Global Analysis- Generic
Release date- 22052013- Alliance Pharma plc, the speciality pharmaceutical company, will hold its Annual General Meeting in London later this morning. Michael Gatenby, the Company's Chairman, will make the following comments:. There have been reduced sales of Nu-SealsTM in Ireland although measures to counteract generic competition are helping to m
Antares Pharma, Inc. today announced the election of Marvin Samson to the Company s Board of Directors. Leonard S. Jacob, M.D., Ph.D., Chairman of the Board of Antares Pharma, stated, I have been an industry colleague of Marvin Samson for many years. I have observed the rapid growth of Antares Pharma over the past few years, and I am excit
Ranbaxy products such as generic Lipitor have been on Oregon pharmacy shelves, and pharmacy board members are concerned over whether enough has been done to protect consumers, said the pharmacy board's executive director, Gary Schnabel. State regulators learned of the case from a Fortune Magazine article, not from the Food and Drug Administration,
Elan Corporation, plc today announced that its Board of Directors, after careful review and consideration and with the assistance of its executive management team as well as outside financial and legal advisors, has determined that privately held investment firm Royalty Pharma's revised offer announced on Monday May 20, 2013 to acquire all of Elan'
Elan Corporation, plc today announced that its Board of Directors, after careful review and consideration and with the assistance of its executive management team as well as outside financial and legal advisors, has determined that privately held investment firm Royalty Pharma's revised offer announced on Monday May 20, 2013 to acquire all of Elan'
Forest Laboratories, Inc., is a pharmaceutical company that develops, manufactures, and sells branded forms of ethical drug products, most of which require a physician's prescription. Our primary and most important products in the United States are marketed directly, or "detailed," to physicians by our salesforces. and Drug Administration approval
CAMBRIDGE, Mass., May 23, 2013 Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will webcast its presentation at two upcoming investor conferences. Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis
According to a release, on March 19, AmerisourceBergen announced that it had entered into a strategic, long-term relationship with Walgreens and Alliance Boots, which includes: a ten-year primary pharmaceutical distribution contract with Walgreens; access to generic drugs and related pharmaceutical products through the Walgreens Boots Alliance...
According to a release, on March 19, AmerisourceBergen announced that it had entered into a strategic, long-term relationship with Walgreens and Alliance Boots, which includes: a ten-year comprehensive primary pharmaceutical distribution contract with Walgreens; access to generic drugs and related pharmaceutical products through the Walgreens Boots
According to a release, on March 19, AmerisourceBergen announced that it had entered into a strategic, long-term relationship with Walgreens and Alliance Boots, which includes: a ten-year comprehensive primary pharmaceutical distribution contract with Walgreens; access to generic drugs and related pharmaceutical products through the Walgreens Boots
By a News Reporter-Staff News Editor at Biotech Week Antares Pharma, Inc. reported operating and financial results for the first quarter ended March 31, 2013. The FDA has assigned a prescription drug user fee act target date of October 14, 2013. Shipped first commercial-ready VIBEX? auto injector devices to Teva for pre-launch quantities of Tev
Attorney General Tim Fox announced today that Montana has joined with other states and the federal government in a $500 million dollar settlement to resolve civil and criminal allegations that Ranbaxy, a generic pharmaceutical manufacturer based in Gurgaon, India, introduced adulterated drugs into interstate commerce. The whistleblower's complaint.
Dublin- Research and Markets has announced the addition of the "Copaxone- Forecast and Market Analysis to 2022" report to their offering. The dominance of first-line injectable DMTs, including the interferon beta agents: Bayer's Betaseron/Betaferon, Biogen's Avonex and Merck's Rebif, and Teva's Copaxone, has been a salient feature of the MS therape
The global pharmaceutical biosimilar market is set for significant growth over the coming years, according to a new Fitch Ratings report. The global biosimilars market is estimated to be $2-3 billion by 2015, concentrated mainly in Europe. The FDA issued draft guidance in February 2012 on how the industry can gain regulatory approval to market bios
PRNewswire iBio, Inc. today announced the production of a vaccine candidate for the newly emerged H7N9 influenza virus by an independent third party laboratory using the iBioLaunch? platform. This validation milestone was achieved in 21 days as measured from initial antigen sequence information to purification of recombinant protein.
